{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"93.4","upperLimit":"99.3","value":"97.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"}],"units":"Participants"}],"description":"EFS is defined as the time from on study to failure to achieve hematological complete response (CR) prior to start of consolidation, persistence of molecular positive disease after minimal residual disease (MRD) positive consolidation course, relapse (molecular, morphologic or extramedullary), or death. The Kaplan-Meier method will be used to estimate 2-year EFS along with 90% log-minus-log transformed confidence limits.","dispersionType":"90% Confidence Interval","groups":[{"description":"WBC \\<10,000 cells/µL","id":"OG000","title":"Standard Risk"}],"paramType":"NUMBER","populationDescription":"Patients ineligible, did not start treatment, or RQPCR positive not confirmed are excluded from analyses of EFS","reportingStatus":"POSTED","timeFrame":"Up to 24 months","title":"Event-free Survival (EFS) in Standard Risk Acute Promyelocytic Leukemia (APL) Patients","type":"PRIMARY","unitOfMeasure":"percentage of participants"}